PLEASE REVIEW OUR PRIVACY & COOKIES NOTICE

We use cookies to collect and analyze information on site performance and usage and to ensure you can successfully navigate throughout the site. By clicking the “ACCEPT” button to your right or by clicking on any site content, you agree to the placement of cookies on your computer. For more information, see our Privacy Policy.

 
Locations
 
WEBSITES
  • United States (English)
  • International (English)
  • Chinese (中文)
  • French (Français)
  • German (Deutsch)
  • Italian (Italiano)
  • Japanese (日本語)
  • Russian (Русский)
 

Leaving U.S. website

You are now leaving the Haemonetics U.S. website, click 'Yes' to continue or 'No' to stay on the U.S. website.

YesNo
  • Investor Relations
  • LOGIN
    • Haemonetics
    • HSS Client Login
    • Software Download Center
  • REGISTER
  • Home
  • Products
     
    U.S. ProductsView International Products
    Devices
    Blood Center Devices
    • ACP 215
    • MCS+ 8150
    • MCS+ 9000
    • NexSys PCS
    • PCS 2
    Plasma Center Devices
    • NexSys PCS with Persona Technology
    • NexSys PCS with YES Technology
    • NexSys PCS
    • PCS 2
    Surgical and Diagnostic Devices
    • Cell Saver Elite+
    • Cell Saver 5+
    • Cell Saver Elite
    • TEG
    Software
    Hospital Software
    • BloodTrack
    • SafeTrace Tx
    Plasma Center Software
    • DMS
    • NexLynk DMS
    • NextGen
    Services
    Consulting Services
    • Process Improvement
     
  • Solutions
     
    Blood Management Solutions
    • Solutions for Blood Centers
    • Solutions for Hospitals
    • Solutions for Plasma Centers
     
  • Learning Center
     
    Product Training
    • All Products
    • Blood Centers
    • Hospitals
    • Plasma Centers
    Thought Leadership
    • White Papers & Clinical Reviews
    • Reference Lists
    • Poster Abstracts
    Education
       
    • About Haemonetics
       
      Company Background
      • Overview
      • Historical Timeline
      • Leadership Team
      • Scientific Advisory Council

      • Office Locations
      Investor Relations
      • Investor Relations Home
      • Stock Information
      • Earnings
      • Forecasts & Guidance
      Corporate Responsibility
      • Corporate Responsibility at Haemonetics
      Donors Make It Matter
      • Donors Make It Matter Campaign
      News & Events
      • In the News
      • Calendar of Events
      • Publications
      Careers
      • Careers Overview
      • Open Positions
      • Our Global HQ

      Grants

      • Grant Program

       
    • Customer Support

    Leaving U.S. website

    You are now leaving the Haemonetics U.S. website, click 'Yes' to continue or 'No' to stay on the U.S. website.

    YesNo
    • Home
    • About Haemonetics
    • Quality
    • Conflict Minerals Statement
    • Contact Us
    • Print
    • Share

    Conflict Minerals Statement

    On August 22, 2012, the U.S. Securities and Exchange Commission (SEC) adopted final rules to implement reporting and disclosure requirements concerning Conflict Minerals, as directed by Section 1502 of the Dodd-Frank Wall Street Reform and Consumer Protection Act of 2010. These rules require manufacturers that file certain reports with the SEC to disclose in a new “Form SD” filing whether the products they manufacture or contract to manufacture contain Conflict Minerals that are “necessary to the functionality or production” of their products – and to report on their process to identify the source of those Conflict Minerals. 

    “Conflict Minerals” currently include gold, cassiterite, columbite/tantalite, and wolframite, specifically tin, tantalum and tungsten, regardless of where these minerals are mined, processed or sold. The U.S. Secretary of State may designate other minerals in the future. 

    The requirements regarding Conflict Minerals were enacted to further the humanitarian goal of ending violent conflict and human rights abuses in the Democratic Republic of the Congo and the surrounding countries of Angola, Burundi, Central African Republic, the Republic of the Congo, Rwanda, South Sudan, Tanzania, Uganda, and Zambia (referred to as the Covered Countries), which have been partially financed by the exploitation and trade of Conflict Minerals. Haemonetics is supportive of efforts to enable supply chain transparency and responsible sourcing. 

    Starting in May 2014, Haemonetics is required to report annually to the SEC with respect to its Conflict Minerals due diligence process. All global suppliers that provide parts contained in Haemonetics products are required to support this effort. Specifically, suppliers are required to respond to a regular survey to identify whether products they manufacture or contract to manufacture for Haemonetics contain any Conflict Minerals necessary to the functionality or production of their products. If any Conflict Minerals are contained in the affected product supplied to Haemonetics, the supplier will be required to determine the country of origin of these materials and whether the Conflict Minerals can be identified as “conflict free,” and to report this information to Haemonetics. 

    Haemonetics will continue to assess the presence of Conflict Minerals in our supply chain. We will educate employees and suppliers about this Conflict Minerals Policy and clearly communicate expectations with regard to supplier performance, transparency and sourcing. We will compare our supplier survey results to information collected via independent conflict free smelter validation programs such as the EICC/GeSI Conflict Free Smelter program.

    • Conflict Minerals Report (January 1, 2019 to December 31, 2019)
    • Contact Us
    • Terms of Use
    • Quality
    • Careers
    • Privacy Policy
    • Site Map

    © 2011-2020 Haemonetics Corporation